0001746473FALSE--12-3100017464732024-09-242024-09-24

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________________________
FORM 8-K
__________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 24, 2024
__________________________________________
PLIANT THERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)
__________________________________________
Delaware001-3930347-4272481
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
   
331 Oyster Point Blvd., South San Francisco, CA
94080
(Address of Principal Executive Offices) (Zip Code)
Registrant’s Telephone Number, Including Area Code: (650) 481-6770
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
__________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 
Trading
Symbol(s)
 Name of each exchange on which registered
Common Stock, par value $0.0001 per share PLRX The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 5.03     Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On September 24, 2024, the Board of Directors of Pliant Therapeutics, Inc. (the “Company”) approved the amendment and restatement of the Bylaws of the Company (as so amended and restated, the “Third Amended and Restated Bylaws”). The Third Amended and Restated Bylaws are effective as of September 24, 2024.
The amendments effected by the Third Amended and Restated Bylaws, among other things: (i) align the Company’s bylaws with developments in Delaware law and jurisprudence; (ii) revise the procedural and disclosure requirements applicable to stockholders’ director nominations and proposals for other business; and (iii) include a provision regarding severability. The Third Amended and Restated Bylaws also implement certain other ministerial and conforming changes.
The foregoing description does not purport to be complete and is qualified in its entirety by the complete text of the Third Amended and Restated Bylaws, a copy of which is filed herewith as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01         Financial Statements and Exhibits.
(d) Exhibits. 
Exhibit
No.
 Description
 
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
1

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 PLIANT THERAPEUTICS, INC.
   
Date: September 27, 2024
By:/s/ Keith Cummings
  Keith Cummings, M.D., MBA
  Chief Financial Officer


2